Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Real-World Comparison of Arthralgias with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease
Selected as a Poster of Distinction Presented on January 23, 2020 Authors: Timothy E. Ritter, MD - GI Alliance, Southlake, TX Chris Fourment, MD - GI Alliance, Southlake, TX Samantha A. Mehta, PharmD - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen,...
Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
Presented on November 26, 2018 Authors: Brian S. Metzger, MD, MPH - Austin Infectious Disease Consultants, Austin, TX John S. Adams, MD, FIDSA, FSHEA - Knoxville Infectious Disease Consultants, P.C., Knoxville, TN Jorge R. Bernett, MD - Infectious Disease Doctors...
Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease
Presented on October 5, 2018 Authors: Annette E. Whitney, MD - Digestive Health Associates of Texas, Dallas, TX; Harry E. Sarles, Jr., MD, FACG - DHAT Research Institute, Richardson, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX...
Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
Presented on October 4, 2017 Authors: Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc., Sugar Land, TX Richard M. Mandel, MD, FIDSA - University of Arizona College of Medicine, Tucson, AZ Ramesh V. Nathan, MD, FIDSA - Mazur, Statner, Dutta, Nathan, PC,...
Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies
Presented on February 22, 2019 Authors: Richard F. Herrscher, MD, FACAAI - AIRCare, Dallas, TX Tidence L. Prince, MD - The Allergy Asthma and Sinus Center, Knoxville Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder,...
Effective Antimicrobial Stewardship for Outpatient Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Diseases Physician Infusion Centers
Presented on November 26, 2018 Authors: Ramesh V. Nathan, MD, FIDSA - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Richard L Hengel, MD - Atlanta ID Group, Atlanta, GA Andrew H Krinsky, MD - Infectious Diseases Associates, Sarasota, FL Thomas K Sleweon, MD...
Evaluation of Bezlotoxumab in Prevention of Recurrent C. Difficile Infection: A multicenter Single-Arm Study in Office Infusion Centers
Presented on October 3, 2018 Richard L. Hengel, MD Timothy E. Ritter, MD Ramesh V. Nathan, MD, FIDSA Lucinda J. Van Anglen, PharmD Stephen W. Marcella Kevin W. Garey, Pharm.D., M.S., FASHP View...
Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers
Presented on November 26, 2018 Authors: Quyen Luu, MD - Central Georgia Infectious Diseases Associates, Macon, GA Barry Statner, MD, FRCPC, FIDSA - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Robin H. Dretler, MD - Infectious Disease Specialists of...
Predictors of Vedolizumab Treatment Persistence in Bio-Naïve Ulcerative Colitis Patients
Timothy E. Ritter - GI Alliance, Southlake, TX Harry E. Sarles - Digestive Health Associates of Texas, Dallas, TX Samantha A. Mehta - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX View...
Real-World Prescribing Patterns of Certolizumab in the Treatment of Crohn’s Disease
Timothy E. Ritter, MD - GI Alliance, Southlake, TX Chris Fourment, MD - GI Alliance, Southlate, TX Samantha A. Kuten, PharmD - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX View...
Onset of Response with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease
Chris Fourment - Texas Digestive Disease Consultants, PA, Southlake, TX Timothy E. Ritter - Texas Digestive Disease Consultants, PA, Southlake, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX...
Second-Line Biologic Therapy After Vedolizumab
Timothy E. Ritter - Texas Digestive Disease Consulatants, PA, Southlake, TX Chris Fourment - Texas Digestive Disease Consulatants, PA, Southlake, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land,...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.